RespireRx Pharmaceuticals Inc. Announces 10 to 1 Reverse Stock Split
January 05, 2021 16:05 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company” or “we”), has, on January 4, 2021, filed with the Secretary of State of...
RespireRx Pharmaceuticals Inc. Announces Appointment of Dr. James Cook and Dr. Jeffrey Witkin as Research Fellows
October 27, 2020 08:55 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Oct. 27, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of Ampakines in the Treatment of Spinal Cord Injury
October 06, 2020 09:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Oct. 06, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Announces Appointment of David Dickason as Senior Vice President Pre-Clinical Product Development
September 25, 2020 09:10 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Sept. 25, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Announces $2 Million Funding Commitment Allowing Option Exercise with UWM Research Foundation, Inc. and Entry into a License Agreement for GABA(A) Receptor Allosteric Neuromodulator Intellectual Property
August 04, 2020 08:45 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), has historically been and remains a leader in the research and...
RespireRx Pharmaceuticals Inc. Announces Extension to Long-Term Employment Contract with Tim Jones as President and Chief Executive Officer
August 03, 2020 15:11 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC: RSPI) (“RespireRx” or the “Company”), is pleased to announce that today, Mr. Tim Jones and RespireRx have...
RespireRx Pharmaceuticals Inc. Announces Appointment of Timothy Jones as President and Chief Executive Officer
May 06, 2020 09:25 ET
|
RespireRX Pharmaceuticals Inc.
Dr. Arnold S. Lippa, Ph.D. to Continue as Executive Chairman of the Board of Directors and Chief Scientific Officer Glen Rock, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc....
RespireRx Pharmaceuticals Inc. Announces Entry into Option Agreement to License GABA(A) Receptor Allosteric Neuromodulator Intellectual Property from the UWM Research Foundation, Inc.
March 04, 2020 09:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 04, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of ampakines for a variety...
RespireRx Pharmaceuticals Inc. CEO Issues Progress and Status Report
February 12, 2020 09:15 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 12, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI), a leader in the development of medicines for respiratory disorders and central nervous system (“CNS”)...
RespireRx Pharmaceuticals Inc. Announces the Filing of Broad Enabling Cannabinoid Continuation-in-Part and New Provisional Patent Applications
February 05, 2020 09:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 05, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...